Established Brands Portfolio

About ANI Pharmaceuticals

ANI Pharmaceuticals has evolved from a generic drug manufacturer into a diversified biopharmaceutical company with a three-pillar strategy: Rare Disease, Generics, and Established Brands. A key achievement was the transformative acquisition of Novitium Pharma, which significantly expanded its R&D capabilities, manufacturing footprint, and specialty portfolio. Under CEO Nikhil Lalwani, the company is focused on delivering sustainable growth by commercializing novel therapies for underserved patient populations while maintaining the stable cash flows of its legacy businesses.

Therapeutic Areas